Found 9 matching trials
A Clinical Study to Evaluate the Safety of Ospemifene PHASE3 The purpose of this study is to determine the efficacy and long-term safety...
Show More Location
Multiple Locations
Learn More & Join Trial
Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus PHASE3 The objective of the study was to assess the long-term safety of daily dose...
Show More Location
Multiple Locations
Learn More & Join Trial
Effects of Ospemifene on Pelvic Vascularity and Blood Flow N/A Subjects will be randomized in a ratio of 1:1 to receive either 60 mg of os...
Show More Location
Multiple Locations
Learn More & Join Trial
Effects of Ospemifene on Brain Activation Patterns in Women With Sexual Interest-arousal Disorders PHASE4 Ospemifene is the first oral and non-hormonal treatment for moderate or sev...
Show More Location
Hospital ClΓnic de Barcelona
Learn More & Join Trial
A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women PHASE3 The purpose of this study is to determine whether ospemifene is more effect...
Show More Location
Multiple Locations
Learn More & Join Trial
Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA PHASE4 This is an unblinded study to be conducted at a single research center, San...
Show More Location
San Diego Sexual Medicine
Learn More & Join Trial
Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity PHASE3 The purpose of this study is to determine the safety and efficacy of ospemi...
Show More Location
Multiple Locations
Learn More & Join Trial
Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause PHASE3 The objective of this study is to evaluate the efficacy and safety of ospem...
Show More Location
Multiple Locations
Learn More & Join Trial
Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus PHASE3 The primary objective of the study was to assess the long-term safety of 30...
Show More Location
Multiple Locations
Learn More & Join Trial